-
UniQure and FDA No Longer in Alignment on Approval Pathway for AMT-130
Latest News
-
Huntexil update: EMA asks for further trial
European Medicines Agency (EMA) tells NeuroSearch a European license for Huntexil in HD requires another large trial
-
KMO inhibitor drug improves lifespan of Huntington's disease mice
Positive results from tests of a new 'KMO inhibiting' drug in Huntington's disease mice
-
Meet the enemy: neutron ray reveals HD protein structure
Scientists use beams of neutrons to study the structure of clumps of mutant huntingtin protein
-
'Floating' gene-silencing drugs into the brain with exosomes
Exosomes – tiny bubbles made by cells – could be used to get gene silencing drugs from the bloodstream into the brain
-
Improving Huntington's disease clinical trial recruitment through patient and family education
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
-
Chubby mice reveal the importance of the hypothalamus in Huntington's disease
Huntington's disease mice are fat but HD patients lose weight – is a brain area called the hypothalamus to blame?
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-
Successful gene therapy trial in Parkinson’s Disease gives hope for HD
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD